Ascletis Pharma’s ASC30 Shows Positive Results in US Phase Ib Obesity Study
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive interim results from a Phase Ib study...
Obesity
Laekna Submits Revised Protocol for LAE102 Obesity Trial with Eli Lilly
Sino-US biotech Laekna Therapeutics (HKG: 2105) announced the submission of a revised clinical protocol to...
Hengrui Pharmaceuticals Gets NMPA Green Light for HRS-1738 and HRS-5817 Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical Products...
United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement...
Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), the distribution partner for US giant Merck’s Gardasil...
Harbour BioMed Launches Élancé Therapeutics to Tackle Obesity Treatment Challenges
China-based Harbour BioMed (HKG: 2142) announced the establishment of Élancé Therapeutics, a new subsidiary focused...
Roche and Zealand Pharma Collaborate to Develop Petrelintide for Weight Management
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced a strategic exclusive collaboration and licensing...
Ascletis Pharma’s ASC47 Shows Positive Results in Phase Ib Study for Weight Loss
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive topline results from a Phase Ib clinical...
NovoCare Pharmacy Offers Reduced-Cost Wegovy for Cash-Paying Patients
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient...
Huadong Medicine’s HDM1005 Receives NMPA Approval for Clinical Trials
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...
Tonghua Dongbao’s Tongboli Under GMP Inspection in Egypt
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced that the on-site Good Manufacturing Practice (GMP) inspection...
AbbVie Enters Obesity Field with Gubra’s GUB014295 Licensing Deal
US pharmaceutical giant AbbVie (NYSE: ABBV) announced that it is making significant progress in the...
Zhongsheng Pharmaceutical’s RAY1225 Gets Green Light for Phase III Study
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval in...
Eli Lilly Launches New Zepbound Doses with Lower Prices for Self-Pay Patients
Eli Lilly & Co. (NYSE: LLY) announced the launch of 7.5 mg and 10 mg...
Huadong Medicine’s HDM1005 Receives NMPA Approval for OSA Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its HDM1005, a long-acting GLP-1/GIP receptor...
Huadong Medicine’s HDM1005 Shows Positive Results in Phase Ia/Ib Study
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced positive results from the Phase Ia/Ib study...
Eli Lilly’s Q4 Sales Soar 45% to $13.53B on Strength of GLP-1 Drugs
Eli Lilly & Co. (NYSE: LLY) reported a robust finish to 2024, with Q4 revenues...
Novo Nordisk’s Amycretin Shows Promising Weight Loss Results in Phase Ib/IIa Study
Denmark – based pharmaceutical giant Novo Nordisk A / S (NYSE: NVO) has announced topline...
Novo Nordisk’s Semaglutide 7.2 mg Shows Superior Weight Loss in Phase III Study
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced positive headline results from the Phase III...
Hengrui and Kailera Announce Positive Phase II Results for HRS9531 in Weight Loss
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) and its US partner Kailera Therapeutics, Inc....